Week of August 30th 2021 | Vol. 10, Issue 35
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
With a self-proclaimed “Super Plant” already on the way in South Korea, Samsung Biologics CEO John Rim said in January that the CDMO’s expansion push was just getting started. He wasn’t kidding.

The manufacturer’s parent company Samsung Group is investing an eye-popping 240 trillion won ($205 billion) through 2023 across its biopharmaceutical, semiconductor and telecommunications businesses, among others, the company said in an emailed statement. 

The cash will help pave the way for future growth and "prepare for economic and societal changes beyond the post-COVID-19 era," the company said. It'll boost various Samsung outfits, including its biosimilars business Samsung Bioepis and its contract manufacturing unit Samsung Biologics, which recently started chipping in on production of Moderna’s COVID-19 vaccine.
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
9 transactions totaling $1,732 million
Supplies, Equipment & Services
12 transactions totaling $49 million
Healthcare IT & Managed Care
9 transactions totaling $857 million
Healthcare Facilities & Distributors
8 transactions totaling $254 million
Pharma & Biotech
22 transactions totaling $446 million
Supplies, Equipment & Services
30 transactions totaling $284 million
Healthcare IT & Managed Care
19 transactions totaling $163 million
Healthcare Facilities & Distributors
0 transactions
Pharma & Biotech
4 transactions totaling $124 million
Supplies, Equipment & Services
5 transactions totaling $22 million
Healthcare IT & Managed Care
1 transaction totaling $15
Healthcare Facilities & Distributors
2 transactions totaling $29 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
August 27, 2021 - Fierce Biotech
Lynk Pharmaceuticals picked up $50 million in series B funds Friday to bankroll three assets through phase 1 and 2 trials. The Hangzhou, China-based biotech has received the green light to run clinical trials for three drugs in the U.S. and China. The biotech also received clinical trial approval in China for its kinase inhibitor aimed at treating inflammatory bowel disease in June.

August 26, 2021 - Contract Pharma
EOC Pharma, an oncology specialty biopharmaceutical company in China, and Chime Biologics, a contract development and manufacturing organization (CDMO), have extended their partnership on the CMC development of EOC202, a recombinant LAG-3 protein for cancer immunotherapy. The extended partnership will enable Chime's world-class biologics development and manufacturing capability and capacity to become part of EOC's engine to fuel the EOC202's clinical development and potential commercial supply in China.

August 25, 2021 - PR Newswire
Vesey Street Capital Partners, LLC ("VSCP"), a New York-based healthcare services private equity firm, announced that funds managed by VSCP have completed a recapitalization of Safecor Health ("Safecor" or the "Company"). The Company is the market leader of pharmaceutical unit dose packaging services for hospitals and health systems and provides unit dose packaging services to pharmaceutical manufacturers and digital pharmacy companies. Terms of the transaction were not disclosed.

August 24, 2021 - Business Wire
Azurity Pharmaceuticals, Inc. (“Azurity”) and Arbor Pharmaceuticals, Inc. (“Arbor”) today announced they have entered into a definitive agreement in which Azurity will be acquiring Arbor from existing investors including JW Asset Management and KKR. Following the completion of the transaction, which is subject to regulatory approvals, Azurity and Arbor will merge, creating a leading company offering innovative, high-value products to meet the unique needs of patients with underserved conditions.
Events Hosted or Attended by Bourne Partners

October 20, 2021 - Charlotte, NC

November 9-11, 2021 - Milan, Italy

January 10-14, 2022 - San Francisco, CA
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.